Detalhe da pesquisa
1.
CDK7-dependent transcriptional addiction in triple-negative breast cancer.
Cell
; 163(1): 174-86, 2015 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26406377
2.
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
Lancet Oncol
; 25(3): 317-325, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342115
3.
Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling.
BMC Genomics
; 25(1): 251, 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448820
4.
Interleukin-3 production by basal-like breast cancer cells is associated with poor prognosis.
Growth Factors
; : 1-13, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299881
5.
Stromal cell diversity associated with immune evasion in human triple-negative breast cancer.
EMBO J
; 39(19): e104063, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32790115
6.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 401(10390): 1773-1785, 2023 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37086745
7.
A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bß1 integrin to sustain breast cancer stem cells.
Genes Dev
; 29(1): 1-6, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25561492
8.
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Breast Cancer Res Treat
; 195(3): 275-287, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35915198
9.
Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing.
Breast Cancer Res Treat
; 191(3): 501-511, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34853987
10.
Estrogen receptor signaling is reprogrammed during breast tumorigenesis.
Proc Natl Acad Sci U S A
; 116(23): 11437-11443, 2019 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31110002
11.
Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Breast Cancer Res
; 23(1): 82, 2021 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34344433
12.
Amplitude modulation of androgen signaling by c-MYC.
Genes Dev
; 27(7): 734-48, 2013 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23530127
13.
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Breast Cancer Res
; 22(1): 87, 2020 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32787886
14.
Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.
Breast Cancer Res
; 22(1): 63, 2020 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32527287
15.
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.
Nature
; 508(7494): 103-107, 2014 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24670641
16.
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.
Breast Cancer Res
; 21(1): 43, 2019 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30898150
17.
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
Breast Cancer Res Treat
; 174(1): 271-278, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30465154
18.
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary.
Med J Aust
; 211(5): 224-229, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31318068
19.
The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer.
Int J Mol Sci
; 20(3)2019 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30720718
20.
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia.
Clin Endocrinol (Oxf)
; 89(3): 280-296, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29741296